MASS SPECTROMETRY AS A TOOL FOR MINIMAL RESIDUAL DISEASE DETECTION IN THE BLOOD OF MYELOMA PATIENTS

por Jacobs, J.F.M.
Publicado 2023

B03 CARFILZOMIB AND LENALIDOMIDE FOR PRIMARY PLASMA CELL LEUKEMIA: FINAL RESULTS OF THE PROSPECTIVE PHASE 2 EMN12/HOVON-129 STUDY FOR PATIENTS AGED ≥66 YEARS

por Musto, P., Minnema, M.C., Roeloffzen, W.W.H., Capra, A., van der Holt, B., Juul Vangsted, A., Broyl, A., Schjesvold, F., Lund, T., Silkjaer, T., Benjamin, R., Grasso, M., Lung Wu, K., Caers, J., Cavo, M., Hájek, R., Bruno, B., Gadisseur, A., Pietrantuono, G., Offidani, M., Pour, L., Sonneveld, P., Boccadoro, M., van de Donk, N.
Publicado 2023

P56 SURVIVAL BENEFIT OF BIRTAMIMAB IN MAYO STAGE IV AL AMYLOIDOSIS IN THE PHASE 3 VITAL STUDY WAS CONSISTENT ACROSS ALL KEY BASELINE VARIABLES

por Gertz, M., Cohen, A., Comenzo, R., Kastritis, E., Landau, H., Libby, E., Liedtke, M., Sanchorawala, V., Schönland, S., Wechalekar, A., Ando, Y., Koh, Y., Zonder, J., Palladini, G., Nie, C., Karp, C., Jin, Y., Conrad, A., Kinney, G., Merlini, G.
Publicado 2023

P39 DEDALO: PHASE II STUDY OF DARATUMUMAB PLUS POMALIDOMIDE AND DEXAMETHASONE (DPD) IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA AND 17P DELETION

por Montefusco, V., Cafro, A.M., Margiotta Casaluci, G., Patriarca, F., Mina, R., D’Agostino, M., Capra, A., Priola, C., Dalla Palma, B., Rizzi, R., Genua, A., Petrucci, M.T., Paris, L., Belotti, A., Cavo, M., Conticello, C., Carlo-Stella, C., Boccadoro, M
Publicado 2023

P09 DARATUMUMAB PLUS LENALIDOMIDE AND DEXAMETHASONE (D-RD) VERSUS LENALIDOMIDE AND DEXAMETHASONE (RD) ALONE IN TRANSPLANT-INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA...

por Weisel, K., Kumar, S., Moreau, P., Bahlis, N., Facon, T., Plesner, T., Orlowski, R., Basu, S., Nahi, H., Hulin, C., Quach, H., Goldschmidt, H., O’Dwyer, M., Perrot, A., Venner, C., Raje, N., Tiab1, M., Macro, M., Frenzel, L., Leleu, X., Pei, H., Krevvata, M, Carson, R, Borgsten, F., Usmani, S.
Publicado 2023

P31 SINGLE-AGENT BELANTAMAB MAFODOTIN IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: FINAL ANALYSIS OF THE DREAMM-2 TRIAL

por Nooka, A., Cohen, A., Lee, H., Badros, A., Suvannasankha, A., Callander, N., Abdallah, A., Trudel, S., Chari, A., Libby, E., Chaudhry, M., Hultcrantz, M., Kortüm, K.M., Richardson, P., Popat, R., Sborov, D., Hakim, S., Lewis, E., Bhushan, B., Gorsh, B., Gupta, I., Opalinska, J., Lonial, S.
Publicado 2023

Microsurgical Resection of Vascular Malformations of the Upper Extremity

por Horan, Katelyn M. H., Beijnen, Usha E. A., Upton, Joseph, Taghinia, Amir H.
Publicado 2023

P64 A CASE OF COVID-19 PNEUMONIA AFTER CAR T-CELL THERAPY IN A PATIENT AFFECTED BY RELAPSED/REFRACTORY MULTIPLE MYELOMA

por Ielo, C., Fazio, F., Rocchi, S., Rizzello, I., Zamagni, E., Petrucci, MT
Publicado 2023

P04 MULTIPARAMETRIC FLOW CYTOMETRY REFINES RISK STRATIFICATION IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS

por Fazio, F., Lapietra, G., Limongi, M. Z., Intoppa, S., Milani, M. L., Piciocchi, A., Martelli, M., Guarini, A., Foà, R., De Propris, M. S., Petrucci, M. T.
Publicado 2023

AL AMYLOIDOSIS UPFRONT TREATMENT AND CURRENT AND FUTURE STUDIES

por Kastritis, E.
Publicado 2023

EARLY DETECTION AND SCREENING FOR MULTIPLE MYELOMA PRECURSORS

por Thorsteinsdottir, S.
Publicado 2023

A Case of Fibula Regeneration after Below-the-knee Amputation in an Adult

por Fukuba, Michiko, Dogo, Kyoko, Saito, Koji, Ishida, Tsuyoshi, Yamaoka, Hisayo, Okochi, Masayuki, Ogata, Naoshi, Komuro, Yuzo
Publicado 2023

P27 HIGH DOSE CYCLOPHOSPHAMIDE AS MOBILIZATION REGIMEN IN NEWLY DIAGNOSED MULTIPLE MYELOMA: SAFETY AND EFFICACY IN AN OUTPATIENT SETTING. SINGLE CENTER EXPERIENCE

por Massarotti, L., Branca, A., Pavan, L., Maroccia, A., Cavarretta, C.A., Ruocco, V., Zatta, I., Scapinello, G., Piazza, F., D’Amore, F., Lessi, F., Gurrieri, C., Zambello, R., Trentin, L., Berno, T.
Publicado 2023

P26 LANDSCAPE OF RECURRENT CYTOGENETIC ABNORMALITIES IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AS DETECTED BY CHROMOSOME MICROARRAY ANALYSIS (CMA)

por Varshavsky Yanovsky, A., Shestovska, Y., Pei, J., Mackrides, N., Fung, H., Nejati, R.
Publicado 2023

Time to Radiation after Oncoplastic Reduction versus After Lumpectomy

por Marxen, Troy, Chan, Patricia, Baker, Nusaiba, Godette, Karen D., Styblo, Toncred M., Carlson, Grant W., Losken, Albert
Publicado 2023

P21 EFFECTIVENESS AND SAFETY OF DELAYED BORTEZOMIB, THALIDOMIDE AND DEXAMETHASONE (VTD) REGIMEN

por Del Fabro, V., Schininà, G., Sapuppo, G., Uccello, G., Gentile, M., Palumbo, F., Romano, A., Di Raimondo, F., Conticello, C.
Publicado 2023

P33 EFFECTIVENESS AND SAFETY OF BELANTAMAB MAFODOTIN IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA IN REAL-LIFE SETTING: THE ALFA STUDY

por Roussel, M., Texier, N., Germain, R., Sapra, S., Paka, P., Kerbouche, N., Colin, X., Leleu, X.
Publicado 2023

P50 OVERALL SURVIVAL ADVANTAGE OF MONOCLONAL ANTIBODIES BASED-TREATMENTS IN MULTIPLE MYELOMA PATIENTS RELAPSED AFTER ALLOGENEIC STEM CELL TRANSPLANTATION

por Nozzoli, C., Pucillo, M., Martino, M., Giaccone, L., Rambaldi, A., Benedetti, E., Russo, D., Mordini, N., Bernasconi, P., Mangiacavalli, S., Pioltelli, P., Carluccio, P., Galieni, P., Ladetto, M., Sica, S., Isola, M., De Martino, M., Oldani, E., Degrandi, E., Biasco, A., Fanin, R., Saccardi, R., Ciceri, F., Patriarca, F.
Publicado 2023

HOW TO HARNESS NEW IMMUNOTHERAPIES WITH COMBINATION STRATEGIES?

por Einsele, H.
Publicado 2023

B06 HIGH LEVELS OF CIRCULATING PLASMA CELLS AT DIAGNOSIS ARE PREDICTIVE FOR WORSE PROGNOSIS IN BOTH TRANSPLANT-ELIGIBLE AND -INELIGIBLE PATIENTS WITH MULTIPLE MYELOMA

por Malandrakis, P., Ntanasis-Stathopoulos, I., Kostopoulos, I.V., Roussakis, P., Eleutherakis-Papaiakovou, E., Panteli, C., Angelis, N., Spiliopoulou, V., Orologas-Stavrou, N., Theodorakakou, F., Fotiou, D., Migkou, M., Gavriatopoulou, M., Kastritis, E., Tsitsilonis, O.E., Dimopoulos, M.A., Terpos, E.
Publicado 2023